Evidence map›Paper›PMID 38454372›Full record

ArticleBMC geriatrics2024

Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries.

Anna Lukačišinová, Jindra Reissigová, Maja Ortner-Hadžiabdić, Jovana Brkic, Betul Okuyan, Daisy Volmer, Ivana Tadić, Pilar Modamio, Eduardo L Mariño, Konstantine Tachkov and 6 more

Open access · goldAbstract read
In one paragraph

Article in BMC geriatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 11 countries.

Anna LukačišinováDepartment of Social and Clinical Pharmacy - Research Group "Ageing, Polypharmacy and Changes in the Therapeutic Value of Drugs in the Aged", Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, Hradec Králové, 500 05, Czech Republic. lukacisinova.anna@gmail.com.ORCID 0000-0001-6461-5977
Jindra ReissigováDepartment of Statistical Modelling, Institute of Computer Science of the Czech Academy of Sciences, Prague, Czech Republic.
Maja Ortner-HadžiabdićCenter for Applied Pharmacy, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.
Jovana BrkicDepartment of Social and Clinical Pharmacy - Research Group "Ageing, Polypharmacy and Changes in the Therapeutic Value of Drugs in the Aged", Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, Hradec Králové, 500 05, Czech Republic.
Betul OkuyanDepartment of Clinical Pharmacy, Faculty of Pharmacy, Marmara University, Istanbul, Turkey.
Daisy VolmerFaculty of Medicine, Institute of Pharmacy, University of Tartu, Tartu, Estonia.
Ivana TadićFaculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Pilar ModamioClinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and Pharmaceutical Technology, and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.
Eduardo L MariñoClinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and Pharmaceutical Technology, and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.
Konstantine TachkovFaculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
Rosa LiperottiFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Graziano OnderFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Harriet Finne-SoveriFinnish Institute for Health and Welfare, Helsinki, Finland.
Hein van HoutDepartment of General Practice, Amsterdam Public Health Research Institute, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands.
Elizabeth P HowardConnell School of Nursing, Boston College, Chestnut Hill, MA, USA.
Daniela FialováDepartment of Social and Clinical Pharmacy - Research Group "Ageing, Polypharmacy and Changes in the Therapeutic Value of Drugs in the Aged", Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, Hradec Králové, 500 05, Czech Republic.
Charles University · CZUniversità Cattolica del Sacro Cuore · ITUniversitat de Barcelona · ESBoston College · USCzech Academy of Sciences · CZFinnish Institute for Health and Welfare · FIMarmara University · TRMedical University of Sofia · BGUniversity of Belgrade · RSUniversity of Hradec Králové · CZUniversity of Tartu · EEUniversity of Zagreb · HRVrije Universiteit Amsterdam · NL

Funding

NETPHARM New Technologies for Translational Research in Pharmaceutical Sciences CZ.02.01.01/00/22_008/0004607
6 · The paper itself

Abstract

backgroundThe use of benzodiazepines (BZDs) in older population is often accompanied by drug-related complications. Inappropriate BZD use significantly alters older adults' clinical and functional status. This study compares the prevalence, prescribing patterns and factors associated with BZD use in community-dwelling older patients in 7 European countries.

methodsInternational, cross-sectional study was conducted in community-dwelling older adults (65 +) in the Czech Republic, Serbia, Estonia, Bulgaria, Croatia, Turkey, and Spain between Feb2019 and Mar2020. Structured and standardized questionnaire based on interRAI assessment scales was applied. Logistic regression was used to evaluate factors associated with BZD use.

resultsOut of 2,865 older patients (mean age 73.2 years ± 6.8, 61.2% women) 14.9% were BZD users. The highest prevalence of BZD use was identified in Croatia (35.5%), Spain (33.5%) and Serbia (31.3%). The most frequently prescribed BZDs were diazepam (27.9% of 426 BZD users), alprazolam (23.7%), bromazepam (22.8%) and lorazepam (16.7%). Independent factors associated with BZD use were female gender (OR 1.58, 95%CI 1.19-2.10), hyperpolypharmacy (OR 1.97, 95%CI 1.22-3.16), anxiety (OR 4.26, 95%CI 2.86-6.38), sleeping problems (OR 4.47, 95%CI 3.38-5.92), depression (OR 1.95, 95%CI 1.29-2.95), repetitive anxious complaints (OR 1.77, 95%CI 1.29-2.42), problems with syncope (OR 1.78, 95%CI 1.03-3.06), and loss of appetite (OR 0.60, 95%CI 0.38-0.94). In comparison to Croatia, residing in other countries was associated with lower odds of BZD use (ORs varied from 0.49 (95%CI 0.32-0.75) in Spain to 0.01 (95%CI 0.00-0.03) in Turkey), excluding Serbia (OR 1.11, 95%CI 0.79-1.56).

conclusionsDespite well-known negative effects, BZDs are still frequently prescribed in older outpatient population in European countries. Principles of safer geriatric prescribing and effective deprescribing strategies should be individually applied in older BZD users.

Indexed as

Anxiety DisordersBenzodiazepinesAgedCross-Sectional StudiesEuropeFemaleHumansMalePrevalenceBenzodiazepinesBenzodiazepinesCommunity-dwelling older adultsEuropeGeriatric dosingGeriatric length of therapy

Identifiers

PMID38454372
PMCPMC10921596
OpenAlexW4392543073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.